Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales

Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales

Tumor necrosis factor antagonists are useful in the treatment of several chronic inflammatory immune mediated diseases. Aim: To assess the effects of infliximab in 21 patients with inflammatory arthropaties, refractary to conventional treatment. Patients and methods: Eleven patients with rheumatoid...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Labarca S,Cristián, Massardo V,Loreto, García M,Paula I, Jacobelli G,Sergio
Lenguaje:Spanish / Castilian
Publicado: Sociedad Médica de Santiago 2003
Materias:
Arthritis
Infliximab
Tumor necrosis factor
Acceso en línea:http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872003001000009
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:scielo:S0034-98872003001000009
record_format dspace
spelling oai:scielo:S0034-988720030010000092004-12-07Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habitualesLabarca S,CristiánMassardo V,LoretoGarcía M,Paula IJacobelli G,Sergio Arthritis Infliximab Tumor necrosis factor Tumor necrosis factor antagonists are useful in the treatment of several chronic inflammatory immune mediated diseases. Aim: To assess the effects of infliximab in 21 patients with inflammatory arthropaties, refractary to conventional treatment. Patients and methods: Eleven patients with rheumatoid arthritis, seven with psoriatic arthritis and three with spondyloarthritis were treated. The mean duration of the diseases was 10 years. Infliximab was administered intravenously in a dose of 3 mg/kg body weight. A median of 6 doses in 8 months was administered. Effectiveness was assessed in 19 patients that received three or more doses. Results: Infliximab was effective in 16 patients (10 with rheumatoid arthritis, four with psoriasis and two with spondyloarthritis) and ineffective in three. In responsive patients, a reduction in the number of inflammed joints and morning stiffness and an improvement in functional capacity was observed. Fifteen of the 16 patients perceived an improvement in their health status. This answer was concordant with concomitant medical evaluation in 15. Patients that maintained the treatment felt very well, well or regular, whereas five of six patients that discontinued the treatment felt ill. Thirteen patients had adverse effects. Treatment was discontinued in two patients due to drug induced lupus, allergy in 2, hypertension in one, high costs in three and lack of response in three. Conclusions: Infliximab reduced arthritic activity in 16 of 19 patients with severe treatment refractary arthritis (Rev Méd Chile 2003; 131: 1157-64).info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.131 n.10 20032003-10-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872003001000009es10.4067/S0034-98872003001000009
institution Scielo Chile
collection Scielo Chile
language Spanish / Castilian
topic Arthritis
Infliximab
Tumor necrosis factor
spellingShingle Arthritis
Infliximab
Tumor necrosis factor
Labarca S,Cristián
Massardo V,Loreto
García M,Paula I
Jacobelli G,Sergio
Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
description Tumor necrosis factor antagonists are useful in the treatment of several chronic inflammatory immune mediated diseases. Aim: To assess the effects of infliximab in 21 patients with inflammatory arthropaties, refractary to conventional treatment. Patients and methods: Eleven patients with rheumatoid arthritis, seven with psoriatic arthritis and three with spondyloarthritis were treated. The mean duration of the diseases was 10 years. Infliximab was administered intravenously in a dose of 3 mg/kg body weight. A median of 6 doses in 8 months was administered. Effectiveness was assessed in 19 patients that received three or more doses. Results: Infliximab was effective in 16 patients (10 with rheumatoid arthritis, four with psoriasis and two with spondyloarthritis) and ineffective in three. In responsive patients, a reduction in the number of inflammed joints and morning stiffness and an improvement in functional capacity was observed. Fifteen of the 16 patients perceived an improvement in their health status. This answer was concordant with concomitant medical evaluation in 15. Patients that maintained the treatment felt very well, well or regular, whereas five of six patients that discontinued the treatment felt ill. Thirteen patients had adverse effects. Treatment was discontinued in two patients due to drug induced lupus, allergy in 2, hypertension in one, high costs in three and lack of response in three. Conclusions: Infliximab reduced arthritic activity in 16 of 19 patients with severe treatment refractary arthritis (Rev Méd Chile 2003; 131: 1157-64).
author Labarca S,Cristián
Massardo V,Loreto
García M,Paula I
Jacobelli G,Sergio
author_facet Labarca S,Cristián
Massardo V,Loreto
García M,Paula I
Jacobelli G,Sergio
author_sort Labarca S,Cristián
title Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
title_short Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
title_full Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
title_fullStr Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
title_full_unstemmed Evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
title_sort evaluación del tratamiento con infliximab en enfermos con artritis inflamatoria refractaria a drogas habituales
publisher Sociedad Médica de Santiago
publishDate 2003
url http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872003001000009
work_keys_str_mv AT labarcascristian evaluaciondeltratamientoconinfliximabenenfermosconartritisinflamatoriarefractariaadrogashabituales
AT massardovloreto evaluaciondeltratamientoconinfliximabenenfermosconartritisinflamatoriarefractariaadrogashabituales
AT garciampaulai evaluaciondeltratamientoconinfliximabenenfermosconartritisinflamatoriarefractariaadrogashabituales
AT jacobelligsergio evaluaciondeltratamientoconinfliximabenenfermosconartritisinflamatoriarefractariaadrogashabituales
_version_ 1718436116713963520

Ejemplares similares